This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
| less than a minute read

mRNA Vaccines: a growing and complex IP landscape

The September 2022 edition of the Vaccine Insights journal has been published and includes a commentary article by Robert Burrows and Ellen Lambrix entitled "mRNA Vaccines: a growing and complex IP landscape". This edition of Vaccine Insights was guest edited by Norbert Pardi (Assistant Professor, Department of Microbiology, Perelman School of Medicine at University of Pennsylvania) and focusses on mRNA

The article examines the types of patents that protect key aspects of mRNA vaccine technology and considers the impact of the existing IP landscape and recent patent litigation on future mRNA vaccine development. 

Vaccine Insights is a new peer-reviewed, open-access journal with a translational focus bringing together leading experts from pharma, biotech, academia, and other key stakeholders to address critical issues and put the latest developments into context. 

The article by Robert and Ellen is free to read with a Vaccine Insights account and can be accessed here

The success of mRNA vaccines against COVID-19 has fuelled significant global interest in the development of mRNA vaccines against other infectious diseases and cancer. The COVID-19 pandemic has also highlighted the complex and fragmented nature of the intellectual property landscape relating to mRNA vaccines. 2022 has also seen the first significant patent infringement cases relating to mRNA vaccines.

Tags

patent litigation, life sciences, commercial and ip transactions, biotech, covid